Arising from progenitor cells in the bone marrow, B cells undergo differentiation through a series of stages characterized by the orderly rearrangement and expression of Ig genes (1, 2). However, the very earliest stages of commitment to the B lineage are poorly understood. Before the appearance ofcytoplasmic IgM, committed pre-B lymphocytes can be distinguished by the appearance of class II MHC antigens, followed by the B cell-specific 95-kD surface glycoprotein CD19 (3) . All resting B cells display CD19 antigens, and CD19 expression persists upon activation (4), but is lost upon further differentiation to Ig-secreting plasma cells (4) . Almost all early B cell malignancies show CD19 expression (3). The observation that CD19 undergoes antibody-induced internalization suggests that it may provide a suitable target for immunotoxin-mediated treatment of aggressive forms of B cell lymphomas and leukemias that respond poorly to conventional chemotherapy (5) .
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Results and Discussion To isolate a cDNA clone encoding CD19, an expression library was constructed from the Burkitt lymphoma line Daudi, introduced into COS cells by the DEAEDextran method, and subjected to three rounds ofpanning and reintroduction into Escherichia coli as described (7, 8) . After the third round of panning, one of eight randomly picked colonies yielded DNA that when transfected into COS cells gave a positive indirect immunofluorescence reaction with anti-CD19 mAbs . COS cells transfected with the cDNA clone reacted with all anti-CD19 mAbs tested but with no other mAbs from a large B cell panel (data not shown) . The positive plasmid contained an insert of -1 .9 kb .
RNA blot hybridization analysis revealed a single RNA species of 2 kb whose expression was restricted to B cell lines (Fig. 1) . The highest abundance of the message was observed in the pre-B cell line Nalm-6, followed by the Burkitt lymphoma line Raji . Weaker expression was found in the B-lymphoblastoid lines IM-9 and LESS, while no expression was observed in the plasmacytoma line RPMI 8226, consistent with the observation that CD19 expression is lost upon terminal differentiation to plasma cells (3, 4) . Peripheral T cells, the T cell leukemia line Jurkat, the promyelocytic leukemia line HL60, the promonocytic leukemia line U937, and the hepatoma line HepG2 were all negative for CD19 expression.
DNA blot hybridization analysis showed a simple pattern consistent with a single copy gene (data not shown) .
The nucleotide sequence ofthe cDNA insert consists of 1,920 nucleotides terminating in a poly(A) tail 16 nucleotides downstream ofthe consensus polyadenylation signal (AATAAA) (Fig. 2 a) . An open reading frame, starting at an ATG embedded in an initiation consensus sequence (9) , encodes a protein of 467 amino acids with a predicted molecular weight (Mr) of 51,799 . The first methionine is followed by 19 predominantly hydrophobic amino acids . Excision of these residues, at a site corresponding to the signal peptide cleavage rules predicted by von Heijne (10), yields a mature protein of Mr 49,300 . The resulting extracellular domain would consist of271 residues containing 5 potential N-linked glycosylation sites (Asn-XaaSer/Thr) . The predicted extracellular domain is followed by 28 predominantly hydrophobic amino acids, with the exception of one arginine residue, consistent with a trans- RNA blot hybridization analysis . 20 kg of each RNA sample was electrophoresed through a 1% agarose gel, denatured, transferred to a nylon filter, and hybridized to a s2 P-labeled CD19 cDNA probe. Sources of RNA are indicated. NALM-6 is a pre-B leukemia, IM-9 a B lymphoblastoid line, JY and LESS EBVtransformed B lymphoblastoid lines, Raji a Burkitt lymphoma, RPMI 8226 a plasmcytoma, Jurkat a T cell leukemia; T represents lymphokineactivated peripheral T cells, HL60 and U937 are myeloid leukemia cell lines and HepG2 a hepatoblastoma. membrane region . Although uncommon, charged residues have been observed in the transmembrane domains of a few surface proteins, including the a and a chains of the T cell antigen receptor complex (11) and IgE Fc receptors (12) . The predicted cytoplasmic domain is composed of 148 residues and contains a large number of serine and threonine residues (16 and 17, respectively) providing potential phosphorylation sites. The cytoplasmic domain is also arginine and proline rich (24 and 15 residues, respectively).
The predicted amino acid sequence was compared with the National Biomedical Research Foundation (NBRF) database using the FASTP algorithm. Significant relatedness was found with members of the Ig family, two proteins encoded by EpsteinBarr virus, and the transforming protein int-1. The Ig homology arises from the extracellular domain which is organized into three contiguous Ig-like domains (13) . Domains 1 and 3 have intercysteine distances of 59 and 61 residues, respectively, only slightly shorter than the 62-67 residue intercysteine spacing typical ofV region domains. The sequence surrounding the second cysteine in domains 1 and 3 matches the V region consensus D-X-G/A-XY C. Domain 2 has an intercysteine distance ofonly 39 residues, and the sequence around the second cysteine more closely resembles that from C region domains (13) .
Quantitative sequence comparisons were performed with the ALIGN program of the NBRF Protein Identification Resource (14) . A score for the test sequences >3 SD above the mean for an ensemble of randomly permuted sequences is considered significant (13) . Optimal alignment of CD19 domains 1 and 3 gave a score 4.61 120 8 STAMENKOVIC AND SEED BRIEF DEFINITIVE REPORT SD above the mean. When the two domains were compared with V regions in the NBRF database, domain 3 showed greater homology to various V regions than did domain 1 (Fig. 3) . The greatest similarity was found with a rabbit V/K region, for which a score 9.99 SD above the mean was found, corresponding to a probability of 8 x 10-z4 for an equally good or better match occurring between two proteins of identical composition . Surprisingly, significant homology was found between the cytoplasmic domain of CD19 and the EBV proteins BSLF1 (15) and gp 220/350 (16) , and the transforming protein int-1 (17) . BSLF-1 is a protein of unknown function, while gp 220/350 plays a role in the attachment of EBV to cell membrane (16) . int-1 is implicated in viral mammary tumorigenesis and is expressed in the developing murine nervous system (17) . The ALIGN score for optimal alignment of CD19 and BSLF1, gp 220/350 and int-1 was 8 .42, 4.91, and 7.60 SD above the mean, respectively (Fig. 4) .
The functional significance of the similarities between CD19 and EBV proteins and int-1 is at present unclear. However, the degree ofrelatedness to BSLF1 appears to eliminate coincidence as a plausible explanation . The CD19-related sequences in BSLF1 may have arisen adventitiously, for example as a result of viral capture 
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Optimal alignment between segments of the cytoplasmic domain of CD19 and the EBV protein BSLFI (NBRF code QQBE15) (a), the EBVprotein gp350/220 (NBRF code QQBE21) (b), and the int-1 oncogene (NBRF code TVHUTI). Conserved residues are displayed beneath the aligned sequences; asterisks denote closely related residues . Summary The isolation and expression ofa full-length cDNA clone encoding the B cell-specific glycoprotein CD19 is reported . The sequence of the cDNA predicts a glycosylated integral membrane protein with a precursor molecular weight of 51.8 x 103 and an extracellular domain organized into three contiguous Ig-like sub-domains. The cytoplasmic domain bears significant relatedness to two proteins encoded by the Epstein-Barr virus and the int-1 oncogene. CD19 transcripts are restricted to members of the B cell lineage, being most abundant in pre-B cell lines and least abundant in plasmacytomas .
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